Identification and Validation of PCSK9 As a Prognostic and Immune-related Influencing Factor in Tumorigenesis: a Pan-cancer Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Oct 20

PMID 37860186

Authors

Chao Sun

Guoji Zhu

Conghuan Shen

Shungen Huang

Ruidong Li

Jianhua Li

Zhenyu Ma

Zhengxin Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Proprotein convertase subtilisin/kexin-9 (PCSK9) has been primarily studied in the cardiovascular field however, its role in cancer pathophysiology remains incompletely defined. Recently, a pivotal role for PCSK9 in cancer immunotherapy was proposed based on the finding that PCSK9 inhibition was associated with enhancing the antigen presentation efficacy of target programmed cell death-1 (PD-1). Herein, we provide results of a comprehensive pan-cancer analysis of PCSK9 that assessed its prognostic and immunological functions in cancer.

Methods: Using a variety of available online cancer-related databases including TIMER, cBioPortal, and GEPIA, we identified the abnormal expression of and its potential clinical associations in diverse cancer types including liver, brain and lung. We also validated its role in progression-free survival (PFS) and immune infiltration in neuroblastoma.

Results: Overall, the pan-cancer survival analysis revealed an association between dysregulated PCSK9 and poor clinical outcomes in various cancer types. Specifically, PCSK9 was extensively genetically altered across most cancer types and was consistently found in different tumor types and substages when compared with adjacent normal tissues. Thus, aberrant DNA methylation may be responsible for PCSK9 expression in many cancer types. Focusing on liver hepatocellular carcinoma (LIHC), we found that PCSK9 expression correlated with clinicopathological characteristics following stratified prognostic analyses. PCSK9 expression was significantly associated with immune infiltrate since specific markers of CD8+ T cells, macrophage polarization, and exhausted T cells exhibited different PCSK9-related immune infiltration patterns in LIHC and lung squamous cell carcinoma. In addition, PCSK9 was connected with resistance of drugs such as erlotinib and docetaxel. Finally, we validated PCSK9 expression in clinical neuroblastoma samples and concluded that PCSK9 appeared to correlate with a poor PFS and natural killer cell infiltration in neuroblastoma patients.

Conclusion: could serve as a robust prognostic pan-cancer biomarker given its correlation with immune infiltrates in different cancer types, thus potentially highlighting a new direction for targeted clinical therapy of cancers.

Citing Articles

Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy.

Xu W, Hu M, Lu X, Lao Y, Ma N, Wang Y Int J Biol Sci. 2024; 20(10):3942-3955.

PMID: 39113701 PMC: 11302870. DOI: 10.7150/ijbs.93668.

Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis.

Iyer K, Ivanov J, Tenchov R, Ralhan K, Rodriguez Y, Sasso J J Med Chem. 2024; 67(11):8519-8544.

PMID: 38787632 PMC: 11181335. DOI: 10.1021/acs.jmedchem.4c00568.

Prognostic Value of Levels in Premenopausal Women at Risk of Breast Cancer-Evidence from a 17-Year Follow-Up Study.

Ruscica M, Macchi C, Gandini S, Macis D, Guerrieri-Gonzaga A, Aristarco V Cancers (Basel). 2024; 16(7).

PMID: 38611089 PMC: 11011028. DOI: 10.3390/cancers16071411.

Drug development advances in human genetics-based targets.

Zhang X, Yu W, Li Y, Wang A, Cao H, Fu Y MedComm (2020). 2024; 5(2):e481.

PMID: 38344397 PMC: 10857782. DOI: 10.1002/mco2.481.

References

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G . The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2014; 26(2):259-71. PMC: 6267863. DOI: 10.1093/annonc/mdu450. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Sun Y, Xue J . Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection. Viruses. 2022; 14(3). PMC: 8955100. DOI: 10.3390/v14030581. View

Ru B, Wong C, Tong Y, Zhong J, Zhong S, Wu W . TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019; 35(20):4200-4202. DOI: 10.1093/bioinformatics/btz210. View

Macchi C, Greco M, Favero C, Dioni L, Cantone L, Hoxha M . Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity. Front Cardiovasc Med. 2022; 8:785250. PMC: 8782054. DOI: 10.3389/fcvm.2021.785250. View

Ortona S, Barisione C, Ferrari P, Palombo D, Pratesi G . PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery. J Clin Med. 2022; 11(13). PMC: 9267902. DOI: 10.3390/jcm11133638. View

Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L . Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11):1015-1026. PMC: 5635424. DOI: 10.1056/NEJMoa1613683. View

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

Wu T, Dai Y . Tumor microenvironment and therapeutic response. Cancer Lett. 2016; 387:61-68. DOI: 10.1016/j.canlet.2016.01.043. View

10.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

11.

Malta T, Sokolov A, Gentles A, Burzykowski T, Poisson L, Weinstein J . Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell. 2018; 173(2):338-354.e15. PMC: 5902191. DOI: 10.1016/j.cell.2018.03.034. View

12.

Gammall J, Lai A . Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review. NPJ Precis Oncol. 2022; 6(1):27. PMC: 9021198. DOI: 10.1038/s41698-022-00269-5. View

13.

Yang Z, Zhang M, Peng R, Liu J, Wang F, Li Y . The prognostic and clinicopathological value of tumor-associated macrophages in patients with colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2020; 35(9):1651-1661. DOI: 10.1007/s00384-020-03686-9. View

14.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

15.

Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M . Network analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol. 2017; 13(8):938. PMC: 5572395. DOI: 10.15252/msb.20177703. View

16.

Barbi J, Pardoll D, Pan F . Treg functional stability and its responsiveness to the microenvironment. Immunol Rev. 2014; 259(1):115-39. PMC: 3996455. DOI: 10.1111/imr.12172. View

17.

Marimuthu A, Subbannayya Y, Sahasrabuddhe N, Balakrishnan L, Syed N, Sekhar N . SILAC-based quantitative proteomic analysis of gastric cancer secretome. Proteomics Clin Appl. 2012; 7(5-6):355-66. PMC: 3804263. DOI: 10.1002/prca.201200069. View

18.

Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T . Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021; 6(1):72. PMC: 7896069. DOI: 10.1038/s41392-020-00449-4. View

19.

Stoekenbroek R, Lambert G, Cariou B, Hovingh G . Inhibiting PCSK9 - biology beyond LDL control. Nat Rev Endocrinol. 2018; 15(1):52-62. DOI: 10.1038/s41574-018-0110-5. View

20.

Troiano G, Caponio V, Adipietro I, Tepedino M, Santoro R, Laino L . Prognostic significance of CD68 and CD163 tumor associated macrophages in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol. 2019; 93:66-75. DOI: 10.1016/j.oraloncology.2019.04.019. View